tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alkem Laboratories Reports Strong Q1 FY26 Results with 11% Revenue Growth

Story Highlights
Alkem Laboratories Reports Strong Q1 FY26 Results with 11% Revenue Growth

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Alkem Laboratories Ltd. ( (IN:ALKEM) ) has provided an update.

Alkem Laboratories Ltd. reported an 11% increase in revenue and a 22% rise in net profit for Q1 FY26, driven by strong growth in both domestic and international sales. The company achieved a higher EBITDA margin and outperformed the Indian Pharmaceutical Market in terms of growth, reflecting its strategic focus on value-accretive products and markets.

More about Alkem Laboratories Ltd.

Alkem Laboratories Ltd. operates in the pharmaceutical industry, focusing on the development, manufacture, and sale of pharmaceutical products. The company has a significant presence in both domestic and international markets, with a strategic emphasis on expanding in high-potential non-US markets.

Average Trading Volume: 44,162

Technical Sentiment Signal: Sell

Current Market Cap: 579B INR

Find detailed analytics on ALKEM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1